Meeting
2012 Gastrointestinal Cancers Symposium
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
Authors
Eric Roeland
University of California, San Diego Moores Cancer Center, La Jolla, CA
Eric Roeland , Kelly Anne Shimabukuro , Paul Timothy Fanta , Bethany H. Parker , Michael Hwang , Tony R. Reid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00460603
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 473)
DOI
10.1200/jco.2012.30.4_suppl.473
Abstract #
473
Poster Bd #
B44
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
First Author: Li-Tzong Chen
Poster
2011 ASCO Annual Meeting
The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
First Author: T. Hansen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu